![](/img/cover-not-exists.png)
Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results from the AMPLE trial
Sokolove, Jeremy, Schiff, Michael, Fleischmann, Roy, Weinblatt, Michael E, Connolly, Sean E, Johnsen, Alyssa, Zhu, Jin, Maldonado, Michael A, Patel, Salil, Robinson, William HLanguage:
english
Journal:
Annals of the Rheumatic Diseases
DOI:
10.1136/annrheumdis-2015-207942
Date:
September, 2015
File:
PDF, 739 KB
english, 2015